PEMBROKE, Bermuda, July 29, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital,” “AXIS” or the “Company”) (NYSE: AXS) today announced that it has hired Rahil Jogani to t

Axis Capital Q2 Earnings Call Highlights

03:04pm, Wednesday, 29'th Jul 2026
Axis Capital NYSE: AXS reported second-quarter results marked by higher insurance premiums, continued profitability in its reinsurance business and an increased focus on underwriting discipline as spe
AXIS Capital Holdings Limited (AXS) Q2 2026 Earnings Call Transcript
AXS's Q2 results reflect premium growth, but higher catastrophe losses and weaker investment income weigh on earnings.
The headline numbers for Axis Capital (AXS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Axis Capital (AXS) came out with quarterly earnings of $2.84 per share, missing the Zacks Consensus Estimate of $3.23 per share. This compares to earnings of $3.29 per share a year ago.
For the  second quarter of 2026 , the Company reports: Annualized return on average common equity ("ROACE") of 17.0% and annualized operating ROACE of 14.3% Combined ratio of 93.1% , producing underw
Bank of Nova Scotia increased its position in Axis Capital Holdings Limited (NYSE: AXS) by 65.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchan
Axis Capital (AXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of
PEMBROKE, Bermuda, July 06, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results fo
Axis Capital (AXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AXIS Capital's specialty insurance strength, premium growth and underwriting profitability support growth, while currency exposure and economic uncertainty remain concerns.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE